Logo
x

Search

Subscribe Now

Type-2 Diabetes

AstraZeneca's Forxiga (dapagliflozin) Receives MHLW's Approval for the Treatment of Chronic Kidney Disease in Patients with and without T2D

AstraZeneca's Forxiga (dapagliflozin) Receives MHLW's Approval for the Treatment of Chronic Kidney Disease in Patients with and wi...

  • August 26, 2021
Lilly Presents the Results of Tirzepatide in SURPASS-1 Trial for Type-2 Diabetes at ADA2021

Lilly Presents the Results of Tirzepatide in SURPASS-1 Trial for Type-2 Diabetes at ADA2021

  • June 28, 2021
Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes

Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes

  • March 5, 2021
Lilly Reports Results of Tirzepatide in P-lll SURPASS-3 and 5 Trials for Type-2 Diabetes

Lilly Reports Results of Tirzepatide in P-lll SURPASS-3 and 5 Trials for Type-2 Diabetes

  • February 18, 2021
Novo Nordisk Reports Submission of Label Extension Application to the EMA for Semaglutide (once weekly- 2.0 mg) for T2D

Novo Nordisk Reports Submission of Label Extension Application to the EMA for Semaglutide (once weekly- 2.0 mg) for T2D

  • December 30, 2020
Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial for Type-2 Diabetes

Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial for Type-2 Diabetes

  • December 10, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.